Skyhawk Reports Positive Phase 1/2 Data for Huntington’s Disease Drug

The trial results indicate that SKY-0515, a small molecule RNA splicing modifier, consistently outperformed the external control group across all four metrics of the disease rating scale, including daily function, motor control, and processing speed. Researchers observed that while untreated patients in the comparison database experienced a decline, those receiving the 9 mg dose maintained or improved their baseline scores throughout the duration of the study.

Beyond clinical performance, the drug demonstrated a biological impact by reducing mutant huntingtin protein levels by more than 60% and PMS1 mRNA by over 25% at the 9 mg dose. These mechanisms target the primary drivers of Huntington's pathology. According to Dr. Samuel Frank of the Beth Israel Deaconess Medical Center, the consistent signals observed in function and cognition support the potential of the therapy as it moves into the global FALCON-HD pivotal program.

Currently, the drug is being evaluated in a broader Phase 2/3 study across more than ten countries. With over 200 patients enrolled across both phases, the company aims to address a disease that affects approximately 40,000 symptomatic individuals in the United States alone. Because the treatment is administered as a once-daily oral pill, it offers a noninvasive alternative to existing experimental therapies, which may increase accessibility for patients in rural or underserved regions.